Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03270072 · ClinicalTrials.gov registry record

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients

A clinical trial of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Massachusetts General Hospital.

Active
Registry status
100
Enrollment target
1
Study location

NCT03270072: Active study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Massachusetts General Hospital.

NCT03270072 is a study of Breast Cancer Stage II and Breast Cancer Stage III that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 177-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03270072, a study of Breast Cancer Stage II and Breast Cancer Stage III, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The objective of the study is to serve as a correlative study for patients enrolled on the RadCOMP trial (NCT02603341), a randomized phase III study of stage II and III breast cancer patients treated with either conventional photon radiation or proton beam radiation

Primary Outcome

Comparison of the change in GLS between conventional radiation and proton beam radiation groups. Participants who decrease their GLS by at least 2% 6-8 months following radiation therapy will be considered to demonstrate a significant decrement in GLS.

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2017-10-26
Est. Completion 2026-12-31
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT03270072 still lists

NCT03270072 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 177-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (44% lower).

The record links to 2 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 0 interventions.

NCT03270072 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03270072 about?

NCT03270072 is a clinical study titled "The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients". The objective of the study is to serve as a correlative study for patients enrolled on the RadCOMP trial (NCT02603341), a randomized phase III study of stage II and III breast cancer patients treated with either conventional photon radiation or proton beam radiation

What is the current status of trial NCT03270072?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2017-10-26. Estimated completion is 2026-12-31.

What conditions does trial NCT03270072 study?

This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III.

Who is sponsoring clinical trial NCT03270072?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03270072 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer Stage II

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03270072's enrollment target sits among peer trials

100 8th of 22 higher than 13 of 22 other Breast Cancer Stage II trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer Stage II trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03270072, the US trial registry maintained by the National Library of Medicine. NCT03270072 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.